Baidu
map

处方外流市场规范化 易复诊全面落地医药分开

2018-04-23 鞠姣 健康界

在医药分开、不限制处方外流等政策推动下,外流处方市场不断增长,渐成大势所趋。据米内网数据显示,2018年中国药品市场规模将增至1.76万亿元,受政策因素影响,处方外流的市场规模将突破1300亿元。华创证券的研报认为,如处方院外销售额占处方销售总额的45%,院外处方将新增3000亿元,这一增量将主要由零售药店、第三终端等承接。这也带来了处方院外化市场的快速生长,药企、药店、流通企业、互联网公司

在医药分开、不限制处方外流等政策推动下,外流处方市场不断增长,渐成大势所趋。

据米内网数据显示,2018年中国药品市场规模将增至1.76万亿元,受政策因素影响,处方外流的市场规模将突破1300亿元。华创证券的研报认为,如处方院外销售额占处方销售总额的45%,院外处方将新增3000亿元,这一增量将主要由零售药店、第三终端等承接。这也带来了处方院外化市场的快速生长,药企、药店、流通企业、互联网公司纷纷把眼光聚焦在这个市场,然而受限于技术、运营门槛,以及以利益为导向带来的无序竞争,未来处方外流市场的发展或将呈现区间震荡,但终究会走向合法合规、合情合理。

发展需要规范引导。近乎疯狂生长的外流处方市场,能否持续发展取决于是否走向规范。

在率先成功打造“梧州模式”处方信息共享平台的易复诊总经理马光磊看来,市场规范化需建立符合法规的信息共享平台,让处方外流市场从无序向依据政策、合法合规方向转变。“实现市场规范的主要动力来源于政策。”

2017年2月9日,国务院办公厅发布了《关于进一步改革完善药品生产流通使用政策的若干意见》国办发〔2017〕13号,文件对药品的评审、生产、流通和使用等环节作出了具体规定。文件提出,推进医药分开,医疗机构应按药品通用名开具处方,并主动向患者提供处方。门诊患者可以自主选择在医疗机构或零售药店购药,医疗机构不得限制门诊患者凭处方到零售药店购药。此外,2017年5月,国务院发布的《深化医药卫生体制改革2017年重点工作任务》中也明确提出:探索医疗机构处方信息、医保结算信息与药品零售消费信息互联互通、实时共享。

医改信息先行,医疗改革离不开信息平台的搭建。基于对政策及市场环境的思考,马光磊说:“医药信息平台正在由原来做独立模块向做区域共享发展,百洋智能科技旗下的易复诊正是基于这一理解,通过与政府相关部门及医院合作,共同搭建了处方信息共享平台,研究如何用信息化手段使处方院外化流淌变得规范。”

合规、合情  易复诊处方信息共享平台落地医药分开政策

在新政策的背景下,如何做到合规、合情地进行处方外延是行业关注的焦点。作为一家深耕医药行业多年的企业,百洋医药集团深知行业的痛点,在为医疗行业引进最新的信息化、智能化技术的同时,集团旗下百洋智能科技还积极践行“医药分家、处方外流”的国家医改政策,其自主研发的易复诊处方信息共享平台正推动新型医疗信息化建设,用信息化工具来改善行业效率、解决行业痛点。

在马光磊看来,易复诊处方信息共享平台不是一个软件,也不是一个APP,而是一整套以患者为核心,联合医院、卫生计生、药监、社保等部门以及社会药店,共同建设的实现医疗机构处方信息、医保结算信息和药品零售销售信息互联互通的体系。简单来讲,就诊患者只需在医院办卡综合服务处绑定个人身份证或社保卡及手机号,医生开具处方时在开方类型上选择“外延处方”,输入处方信息,信息经由医院合理用药系统及药师前置审方后,患者的手机上便会收到取药短信,短信的主要内容为患者姓名、处方单、取药码、药店名称和药店地图导航。患者凭借信息就可以就近到药店取药。

信息化手段使处方院外化流淌变得规范,“合规、合情”两大标尺保障了处方院外化流转的合理性。为保证院外处方合情,易复诊平台为患者推荐周边可满足整张处方的药店,满足患者知情权,让其自主选择购买渠道;为保证院外处方的合理,平台确保医生在医院的信息系统下完成外延处方,通过医院合理用药系统内部审核,在药店设置药师进行两次审方;为完善运营流程、保证服务质量,平台开展药店评分制度、用药跟踪机制、诊后健康管理。“处方外流在符合法规的同时合情,不仅保证了处方的合法性,还给予老百姓充分的知情权,使其根据实际需求选择药店。”他说。

“梧州模式”将在全国快速复制

易复诊第一批试点医院——广西梧州红十字会医院,于2017年5月启动了全国首家处方信息共享平台,“梧州模式”也因此备受政府、各级医院、药企、药店的关注。2017年的11月15号,梧州市卫计委相关负责人对外发布,梧州市二级三级所有医院21家入驻平台,基本实现整个梧州门诊药房的医药分开。“长期以来,源于处方真实性、销售真实性无处可查,零售药店统筹报销是困扰政府的难题。而通过处方信息共享平台,核实处方真实性和销售真实性,实现进销存的三次匹配,梧州已实现了部分药品的统筹帐户药店结算,成为易复诊摸索政策落地的又一尝试。”马光磊说,“目前,易复诊业务已扩展到辽宁、陕西、河南、山东、广西、广东等省份。”

对于易复诊而言,在行业优先布局医药信息平台,底气在于百洋医药集团过去十多年深耕医药产业积累的雄厚基础和对市场的敏锐洞察。易复诊打破了方案壁垒,能够适应各地的政策和现实环境;打破了技术壁垒,实现不同医疗接口的数据匹配;打破了产业协同壁垒,可联结配送产业、营销企业,保证真正有服务能力和意愿的药店接得住医院的处方,促进区域药品市场的协同。

未来,百洋智能科技将继续在大健康行业精耕细作,为行业提供更多领先的智能化工具。正如百洋医药集团董事长付钢把百洋的行业布局比作骆驼穿过沙漠:启程前已知晓沙漠有多大,穿行需做哪些储备,一旦走进不要求一路狂奔,而是坚持不懈,靠耐力执着地朝一个方向前进!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691369, encodeId=4b47169136996, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Mon Oct 22 17:18:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409497, encodeId=33fb140949e35, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534916, encodeId=64e6153491679, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573810, encodeId=c82815e3810fc, content=<a href='/topic/show?id=e32142415f5' target=_blank style='color:#2F92EE;'>#处方外流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42415, encryptionId=e32142415f5, topicName=处方外流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a7415955646, createdName=xiaogang322, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308626, encodeId=a69a3086264c, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:42 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691369, encodeId=4b47169136996, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Mon Oct 22 17:18:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409497, encodeId=33fb140949e35, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534916, encodeId=64e6153491679, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573810, encodeId=c82815e3810fc, content=<a href='/topic/show?id=e32142415f5' target=_blank style='color:#2F92EE;'>#处方外流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42415, encryptionId=e32142415f5, topicName=处方外流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a7415955646, createdName=xiaogang322, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308626, encodeId=a69a3086264c, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:42 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-25 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691369, encodeId=4b47169136996, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Mon Oct 22 17:18:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409497, encodeId=33fb140949e35, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534916, encodeId=64e6153491679, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573810, encodeId=c82815e3810fc, content=<a href='/topic/show?id=e32142415f5' target=_blank style='color:#2F92EE;'>#处方外流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42415, encryptionId=e32142415f5, topicName=处方外流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a7415955646, createdName=xiaogang322, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308626, encodeId=a69a3086264c, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:42 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691369, encodeId=4b47169136996, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Mon Oct 22 17:18:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409497, encodeId=33fb140949e35, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534916, encodeId=64e6153491679, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573810, encodeId=c82815e3810fc, content=<a href='/topic/show?id=e32142415f5' target=_blank style='color:#2F92EE;'>#处方外流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42415, encryptionId=e32142415f5, topicName=处方外流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a7415955646, createdName=xiaogang322, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308626, encodeId=a69a3086264c, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:42 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1691369, encodeId=4b47169136996, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Mon Oct 22 17:18:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409497, encodeId=33fb140949e35, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534916, encodeId=64e6153491679, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573810, encodeId=c82815e3810fc, content=<a href='/topic/show?id=e32142415f5' target=_blank style='color:#2F92EE;'>#处方外流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42415, encryptionId=e32142415f5, topicName=处方外流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a7415955646, createdName=xiaogang322, createdTime=Wed Apr 25 11:18:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308626, encodeId=a69a3086264c, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:42 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-23 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

宁波家庭医生配慢性病处方药 药量可增至3个月

自2017年12月起,宁波将进一步完善实施基层医疗机构慢性病门诊用药管理新办法。

美国每年因医生写处方潦草有约50万人受伤害

医生写处方潦草是许多国家都存在的问题,但美国相当严重,美国每年因医生写处方潦草导致约50万人受伤害。

BMC Med:精简低CVD风险患者的预防性心血管药物处方安全吗?

2018年1月,发表在《BMC Med》的一项由荷兰科学家进行的聚类随机非劣效性试验,考察了全科医疗中,心血管疾病风险预计降低的患者中精简预防性心血管药物处方的情况(ECSTATIC研究)。

医生再戴紧箍咒 总药师能停掉医生处方

医生不合理处方再戴一层紧箍咒,这次是药师对医生说“不”。

还去医院卖药?这万亿市场保不住了

日前,天津人社局发布《关于实施维护参保人员基本用药权益有关措施的通知》(下称通知)。着重安排了医院处方外流的的细节。

广东药店将分级 级别不够不可销售处方药

4月11日,广东省食药监局召开新闻通气会,解读加强药品零售企业管理的规范性文件。据介绍,广东将推行药店“分级分类”管理制度,零售药店将分为一类店、二类店和三类店进行管理。其中,一类店只能经营非处方药,二类店可以经营处方药,但不能经营中药饮片,三类店则可以销售非处方药、处方药、中药饮片等所有可在药品零售企业销售的药品。该办法将于4月15日起实施。明确三类药店经营范围据介绍,一类店经营范围限定为非处

Baidu
map
Baidu
map
Baidu
map